Guobang Pharma Ltd.
Shanghai Stock ExchangeTotal Valuation
Guobang Pharma Ltd. carries a market capitalization of 12.46B, placing it among publicly traded companies globally. Its enterprise value stands at 12.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 12.46B |
| Enterprise Value | 12.62B |
Share Statistics
Guobang Pharma Ltd. currently has 782.35M shares outstanding.
| Shares Outstanding | 782.35M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Guobang Pharma Ltd. trades at a trailing price-to-earnings ratio of 26.08. The price-to-sales ratio is 3.10, and the price-to-book ratio stands at 2.97.
| PE Ratio | 26.08 |
| PS Ratio | 3.10 |
| PB Ratio | 2.97 |
| P/TBV Ratio | 1.72 |
| P/FCF Ratio | 66.17 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Guobang Pharma Ltd. trades at an EV/EBITDA multiple of 17.98 and an EV/FCF ratio of 53.31. The EV/Sales ratio of 2.72 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.98 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.72 |
| EV / EBITDA | 17.98 |
| EV / EBIT | 17.98 |
| EV / FCF | 53.31 |
Financial Position
Guobang Pharma Ltd. maintains a current ratio of 2.54, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.41, indicating elevated leverage, while an interest coverage ratio of 31.49 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.54 |
| Quick Ratio | 1.08 |
| Debt / Equity | 11.41 |
| Debt / EBITDA | 1.42 |
| Interest Coverage | 31.49 |
Financial Efficiency
Guobang Pharma Ltd. posts a return on equity of 11.88 and a return on invested capital of 6.35.
| Return on Equity (ROE) | 11.88 |
| Return on Assets (ROA) | 4.90 |
| Return on Invested Capital (ROIC) | 6.35 |
| Return on Capital Employed (ROCE) | 10.11 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.20 |
Taxes
Over the trailing twelve months, Guobang Pharma Ltd. has paid 86.49M in income taxes, reflecting an effective tax rate of 13.60.
| Income Tax | 86.49M |
| Effective Tax Rate | 13.60 |
Stock Price Statistics
Guobang Pharma Ltd.'s stock has gained approximately 9.63524% over the past 52 weeks. The 50-day moving average sits at 16.04, while the 200-day moving average is 17.38.
| Beta (5Y) | N/A |
| 52-Week Price Change | 9.63524% |
| 50-Day Moving Average | 16.04 |
| 200-Day Moving Average | 17.38 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Guobang Pharma Ltd. generated 4.65B in revenue and converted that into 551.80M in net income, yielding earnings per share of 0.71. EBITDA reached 702.11M, while operating income came in at 702.11M.
| Revenue | 4.65B |
| Gross Profit | 1.15B |
| Operating Income | 702.11M |
| Pretax Income | 636.04M |
| Net Income | 551.80M |
| EBITDA | 702.11M |
| EBIT | 702.11M |
| Earnings Per Share (EPS) | 0.71 |
Balance Sheet
Guobang Pharma Ltd. holds 2.77B in cash and equivalents against 994.27M in total debt, resulting in a net debt position of -917.64M. Total book value stands at 4.85B, with working capital of 3.96B providing operational flexibility.
| Cash & Cash Equivalents | 2.77B |
| Total Debt | 994.27M |
| Net Debt | -917.64M |
| Equity (Book Value) | 4.85B |
| Book Value Per Share | 6.25 |
| Working Capital | 3.96B |
Cash Flow
After subtracting -217.52M in capital expenditures, free cash flow totaled -217.52M - equivalent to -0.28 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -217.52M |
| Free Cash Flow | -217.52M |
| FCF Per Share | -0.28 |
Margins
Guobang Pharma Ltd. operates with a gross margin of 24.63, reflecting its pricing power and cost economics. The operating margin of 15.10 and net profit margin of 11.87 provide insight into operational efficiency.
| Gross Margin | 24.63 |
| Operating Margin | 15.10 |
| Pretax Margin | 13.68 |
| Profit Margin | 11.87 |
| EBITDA Margin | 15.10 |
Dividends & Yields
The company's payout ratio of 65.05 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.46 |
| Dividend Yield | N/A |
| Payout Ratio | 65.05 |
| Shareholder Yield | 2.16 |
| FCF Yield | 1.51 |
Stock Splits
Guobang Pharma Ltd.'s most recent stock split took place on May 29, 2026 with a 5:7 split ratio.
| Last Split Date | 5/29/2026 |
| Split Ratio | 5:7 |
Scores
Guobang Pharma Ltd. posts an Altman Z-Score of 4.82, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.82 |